phenserine has been researched along with Alzheimer Disease in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (8.82) | 18.2507 |
| 2000's | 14 (41.18) | 29.6817 |
| 2010's | 14 (41.18) | 24.3611 |
| 2020's | 3 (8.82) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J; Liu, D; Liu, W; Shi, T; Wang, D; Wang, Y; Wang, Z; Yin, G; Zhang, H | 1 |
| Li, X; Wang, S; Wang, Y; Wang, Z; Zhang, H | 1 |
| Chen, XQ; Kleschevnikov, AM; Maccecchini, M; Mobley, WC; Nguyen, PD; Overk, C; Pearn, ML; Salehi, A | 1 |
| Aarsland, D; Ballard, C; Becker, RE; Bledsoe, J; Ferrucci, L; Flanagan, D; Govindarajan, R; Greig, NH; Kapogiannis, D; Lahiri, DK; Majercik, S; Sano, M; Schneider, LS | 1 |
| Bader, M; Becker, RE; Greig, NH; Hoffer, BJ; Hoffman, AF; Hsueh, SC; Jung, YJ; Lecca, D; Lupica, CR; Pick, CG; Tweedie, D | 1 |
| Gonzalez, D; Greig, NH; Lilja, AM; Marutle, A; Mustafiz, T; Nordberg, A; Röjdner, J; Storelli, E; Thomé, CM; Unger-Lithner, C | 1 |
| Balleidier, A; Bandyopadhyay, S; Cahill, C; Huang, C; Huang, X; Lahiri, DK; Rogers, JT | 1 |
| Darreh-Shori, T; Hosseini, SM; Nordberg, A | 1 |
| Lilja, AM; Malmsten, L; Marutle, A; Nordberg, A; Ögren, SO; Röjdner, J; Verkhratsky, A; Voytenko, L | 1 |
| Almkvist, O; Andreasen, N; Kadir, A; Långström, B; Nordberg, A; Wall, A; Zetterberg, H | 1 |
| Merchant, S; Sugaya, K | 1 |
| Lahiri, DK; Schneider, LS | 1 |
| Becker, RE; Bruinsma, G; Friedhoff, LT; Frölich, L; Giacobini, E; Greig, NH; Winblad, B | 1 |
| Chiou, G; Garg, NK; Schammel, AW | 1 |
| Becker, RE; Greig, NH | 2 |
| Reale, M; Tata, AM | 1 |
| Greig, NH; Holloway, HW; Kamal, MA; Lahiri, DK; Luo, W; Ray, B; Reale, M; Rogers, JT; Sambamurti, K; Yu, QS | 1 |
| Greig, NH; Li, Y; Lilja, AM; Luo, Y; Marini, AM; Marutle, A; Nordberg, A; Röjdner, J; Yu, QS | 1 |
| Brossi, A; Bruinsma, GB; Greig, NH; Lahiri, DK; Sambamurti, K; Yu, QS | 1 |
| Thatte, U | 1 |
| Castro, A; Martinez, A | 1 |
| Brossi, A; Chen, D; Davidson, D; Giordano, T; Greig, NH; Holloway, HW; Lahiri, DK; Sambamurti, K; Utsuki, T; Yu, QS | 1 |
| Greig, NH; Holloway, HW; Kamal, MA; Klein, P; Li, Y; Tweedie, D; Yu, QS | 1 |
| Chen, D; Giordano, T; Greig, NH; Holloway, HW; Lahiri, DK; Maloney, B; Sambamurti, K; Utsuki, T; Yu, QS | 1 |
| Klein, J | 1 |
| Alley, GM; Chen, D; Greig, NH; Lahiri, DK; Tweedie, D | 1 |
| Greig, NH; Marutle, A; Nilbratt, M; Nordberg, A; Ohmitsu, M; Sugaya, K | 1 |
| Almkvist, O; Andreasen, N; Blennow, K; Engler, H; Forsberg, A; Hagman, G; Kadir, A; Långström, B; Lärksäter, M; Nordberg, A; Wall, A; Winblad, B; Zetterberg, H | 1 |
| Brossi, A; Greig, NH; Ingram, DK; Pei, XF; Soncrant, TT | 1 |
| Acevedo, LD; Davis, KL; Gluck, R; Greig, N; Haroutunian, V; Pei, XF; Utsuki, T; Wallace, WC | 1 |
| Brossi, A; Greig, NH; Holloway, HW; Utsuki, T; Yu, Q | 1 |
| Al-Jafari, AA; Alhomida, AS; Greig, NH; Kamal, MA | 1 |
| Brossi, A; De Micheli, E; Deutsch, J; Greig, NH; Holloway, HW; Ingram, DK; Lahiri, DK; Perry, TA; Soncrant, TT; Utsuki, T; Yu, QS | 1 |
8 review(s) available for phenserine and Alzheimer Disease
| Article | Year |
|---|---|
Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Ligands | 2022 |
(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Cell Death; Cholinesterase Inhibitors; Humans; Physostigmine | 2018 |
How to approach Alzheimer's disease therapy using stem cell technologies.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cell Differentiation; Cell Proliferation; Cholinesterase Inhibitors; Cognition; Humans; Mice; Neurons; Physostigmine; Rats; Stem Cell Transplantation; Stem Cells | 2008 |
An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Physostigmine; Tartrates | 2005 |
Phenserine Axonyx.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; Molecular Structure; Physostigmine | 2005 |
Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Galantamine; Humans; Physostigmine; Protein Conformation | 2006 |
Phenserine.
Topics: Alzheimer Disease; Animals; Clinical Trials, Phase II as Topic; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Mice; Physostigmine; Risk Assessment; Sensitivity and Specificity; Treatment Outcome | 2007 |
Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Physostigmine; Rats; Structure-Activity Relationship | 1995 |
4 trial(s) available for phenserine and Alzheimer Disease
| Article | Year |
|---|---|
Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Benzothiazoles; Blotting, Western; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Drug Therapy, Combination; Fluorescence; Follow-Up Studies; Humans; Indans; Physostigmine; Piperidines; Thiazoles; Time Factors | 2014 |
Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Biomarkers; Brain; Cognition; Double-Blind Method; Female; Glucose; Humans; Male; Nootropic Agents; Peptide Fragments; Phosphorylation; Physostigmine; Positron-Emission Tomography; tau Proteins; Time Factors; Treatment Outcome | 2015 |
Phenserine efficacy in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Physostigmine; Treatment Outcome | 2010 |
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amyloid; Brain; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Male; Physostigmine; Placebo Effect; Positron-Emission Tomography; Treatment Outcome | 2008 |
22 other study(ies) available for phenserine and Alzheimer Disease
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of carbamate derivatives of N-salicyloyl tryptamine as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Drug Design; Humans; Male; Maze Learning; Molecular Docking Simulation; Neuroprotective Agents; Protein Aggregates; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tryptamines | 2022 |
Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Down Syndrome; Endosomes; Humans; Mice; Neurons; Phenotype; Phosphorylation; Physostigmine | 2021 |
(-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice.
Topics: Alzheimer Disease; Animals; Brain Concussion; Cell Death; Cerebral Cortex; Disease Models, Animal; Hippocampus; Mice; Mice, Transgenic; Neurons; Physostigmine | 2019 |
Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levels.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cell Proliferation; Disease Models, Animal; Doublecortin Protein; Female; Hippocampus; Interleukin-1beta; Male; Mice; Mice, Transgenic; Neuronal Plasticity; Neurons; Physostigmine; Plaque, Amyloid; Synapses; Tumor Necrosis Factor-alpha | 2013 |
Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease.
Topics: 5' Untranslated Regions; alpha-Synuclein; Alzheimer Disease; Amyloid beta-Protein Precursor; Aniline Compounds; Animals; Base Sequence; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; Down Syndrome; Humans; Iron; Iron Regulatory Protein 1; Mice; Mice, Transgenic; Molecular Sequence Data; Neurons; Physostigmine; Protein Binding; Protein Biosynthesis; Response Elements; RNA, Messenger; Sequence Homology, Nucleic Acid | 2013 |
Neural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic α7 Nicotinic Receptor Drugs.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Carbamates; Cell Proliferation; Cognition; Doublecortin Protein; Female; Hippocampus; Humans; Male; Maze Learning; Memory; Mice; Nerve Regeneration; Neural Stem Cells; Neurogenesis; Nicotinic Agonists; Physostigmine; Quinuclidines; Stem Cell Transplantation | 2015 |
The perils of Alzheimer's drug development.
Topics: Alzheimer Disease; Animals; Biomedical Research; Clinical Trials as Topic; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Evaluation; Drug Industry; Humans; Observer Variation; Physostigmine; Selection Bias | 2009 |
Synthesis of (+)-phenserine using an interrupted Fischer indolization reaction.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Indoles; Molecular Structure; Physostigmine; Pyrrolidines; Stereoisomerism | 2012 |
Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; Physostigmine; Research Design; Treatment Failure | 2013 |
Was phenserine a failure or were investigators mislead by methods?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Humans; MEDLINE; Physostigmine; Randomized Controlled Trials as Topic; Research Design; Treatment Failure | 2012 |
Editorial (hot topic:modulation of cholinergic system activity in neuronal and non-neuronal tissues: therapeutic implications).
Topics: Acetylcholine; Alzheimer Disease; Butyrylcholinesterase; Cholinergic Agents; Humans; Inflammation; MicroRNAs; Physostigmine | 2013 |
Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholinergi
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Protein Precursor; Humans; Interleukin-1beta; Physostigmine; Plaque, Amyloid; Receptors, Muscarinic; Receptors, Nicotinic; Stereoisomerism | 2013 |
Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doublecortin Protein; Drug Discovery; Gene Expression Regulation; Humans; Mice; Mice, Transgenic; Mutation; Neural Stem Cells; Neurons; Neuroprotective Agents; Oxidative Stress; Peptide Fragments; Physostigmine; Stereoisomerism | 2013 |
Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Blotting, Western; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Enzyme-Linked Immunosorbent Assay; Extracellular Space; Humans; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neuroprotective Agents; Physostigmine; RNA, Messenger; Stereoisomerism; Structure-Activity Relationship | 2006 |
Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Physostigmine; Time Factors | 2006 |
The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Cell Line, Tumor; Cerebral Cortex; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Inbred C57BL; Physostigmine; RNA, Messenger; Stereoisomerism | 2007 |
Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Butyrylcholinesterase; Carbamates; Cell Line; Cell Survival; Cholinesterase Inhibitors; Humans; Indoles; Molecular Structure; Neurons; Physostigmine; Pyrroles | 2007 |
Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine.
Topics: Alzheimer Disease; Amyloid; Animals; Cell Differentiation; Cells, Cultured; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Humans; Mice; Mice, Transgenic; Neuroglia; Neurons; Physostigmine; Stem Cell Transplantation; Stem Cells | 2007 |
Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Isoflurophate; Male; Muscarinic Antagonists; Physostigmine; Prosencephalon; Rats; Rats, Sprague-Dawley; Scopolamine | 1997 |
Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Erythrocytes; Humans; Physostigmine; Structure-Activity Relationship | 1999 |
Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding, Competitive; Cholinesterase Inhibitors; Humans; Kinetics; Physostigmine | 2000 |
The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.
Topics: Administration, Oral; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Disease Models, Animal; Half-Life; Infusions, Intravenous; Male; Physostigmine; Rats; Rats, Inbred F344; Tacrine | 2000 |